Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 53

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 8
Chunk 53
---
 about the assumptions
a market participant would use in pricing the instrument.

The
following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of July 31, 2025 (in thousands):

 SCHEDULE OF FINANCIAL ASSETS MEASURED AT FAIR VALUE ON A RECURRING BASIS

    Level
    1  
    Level
    2  
    Level
    3  
    Total 
  
    Money
    market funds: 

    Cash
    equivalents 
    $1,448  
    $-  
    $-  
    $1,448 
  
    Bitcoin
    exchange traded funds: 

    Short-term
    investments 
     -  
     12  
     -  
     12 
  
    U.S.
    treasury bills: 

    Short-term
    investments 
     -  
     14,522  
     -  
     14,522 
  
    Total
    financial assets 
    $1,448  
    $14,534  
    $-  
    $15,982 

    13

The
following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2024 (in
thousands):

    Level
    1  
    Level
    2  
    Level
    3  
    Total 
  
    Money
    market funds: 

    Cash
    equivalents 
    $1,170  
    $-  
    $-  
    $1,170 
  
    U.S.
    treasury bills: 

    Short-term
    investments 
     -  
     18,653  
     -  
     18,653 
  
    Total
    financial assets 
    $1,170  
    $18,653  
    $-  
    $19,823 

Our
non-financial assets that are measured at fair value on a non-recurring basis are property and equipment and other assets which are measured
using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair
value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts
due to the short-term nature of these measurements. Cash equivalents are stated at